Leptin-mediated meta-inflammation may provide survival benefit in patients receiving maintenance immunotherapy for extensive-stage small cell lung cancer (ES-SCLC).
Vita E, Stefani A, Piro G, Mastrantoni L, Cintoni M, Cicchetti G, Sparagna I, Monaca F, Horn G, Russo J, Barone D, Di Salvatore M, Trisolini R, Lococo F, Mazzarella C, Cancellieri A, Carbone C, Larici AR, Mele MC, Pilotto S, Milella M, Tortora G, Bria E.
Vita E, et al. Among authors: di salvatore m.
Cancer Immunol Immunother. 2023 Nov;72(11):3803-3812. doi: 10.1007/s00262-023-03533-0. Epub 2023 Sep 5.
Cancer Immunol Immunother. 2023.
PMID: 37668709
Free PMC article.